Efficacy of Ventavis Used in Real-life Setting. (SPHERA)

Bayer

Status: Completed

Conditions: Pulmonary Arterial Hypertension

Treatments: Drug: Inhaled iloprost (Ventavis, BAYQ6256)

Study type: Observational

Funder types: Industry

Identifiers

NCT01355380

15308

VE1010PL (Other Identifier)

Details and patient eligibility

About

This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis.

Typical clinical measures and quality of life will be prospectively followed in 12 months period.

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pulmonary arterial hypertension in WHO functional class III or IV
• Age 18+
• Patients newly treated with Ventavis or switched from sildenafil

Exclusion criteria

• Retrospective documentation is not allowed

Trial design

55 participants in 1 patient group

Group 1

Description:

Drug (incl. Placebo)

Treatment:

Drug: Inhaled iloprost (Ventavis, BAYQ6256)